Shares of Dova Pharmaceutical (NASDAQ: DOVA) surged 35% Thursday morning following reports the FDA has approved marketing application for DOPTELET which is used to treat low blood platelets in adults.
- DOPTELET marketing material approved by FDA
- Dova shares up 35% on robust volume premarket
- DOPTELET treats low blood pressure in adults
- Shares haven’t traded this high since December
“Dova is pleased to provide DOPTELET to patients and physicians in the United States for the treatment of chronic ITP in adult patients who have had an insufficient response to a previous treatment,” said Dr. David Zaccardelli, president and CEO of Dova. “In addition to offering patients with ITP a new treatment option, we expect DOPTELET will also address an important unmet medical need in the market. We sincerely thank the patients and dedicated researchers who participated in our clinical program as well as FDA for their collaboration during the review of this application.”
Dova Pharmaceuticals Inc is the United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases.
It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.
The company’s drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company’s drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.